Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.41 |
| ▸ | ALPL | P05186 | 2/20 | 0.39 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29699355 | 0.86 | SCN9A (0.59) | KMOSCN9AGRIN2BALPLSLC1A5 | |
| SCHEMBL474418 | 0.74 | ALDH1A1 (0.53) | KMOSCN9ATRPA1TRPV4 | |
| SCHEMBL14742275 | 0.73 | KMO (0.68) | KMOGRIN2B | |
| SCHEMBL29699454 | 0.73 | KMO (0.45) | KMOGRIN2BSLC1A5GRM2PPARD | |
| SCHEMBL22815581 | 0.73 | KMO (0.50) | KMOSCN9AGRIN2BSLC1A5TRPA1 | |
| SCHEMBL14742214 | 0.72 | KMO (0.60) | KMOGRIN2BSLC1A5 | |
| SCHEMBL14741867 | 0.72 | KMO (0.51) | KMOGRIN2BSLC1A5GRM2 | |
| SCHEMBL5537301 | 0.71 | KMO (0.52) | KMOGRIN2BSLC1A5GRM2 | |
| SCHEMBL5545853 | 0.70 | KMO (0.53) | KMOSCN9AGRIN2BSLC1A5GRM2 | |
| SCHEMBL6002878 | 0.69 | MRGPRX4 (0.53) | KMOSCN9AGRIN2BGRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 248/4885SCN9A 2941/4885GRIN2B 1562/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 255/4885SCN9A 3323/4885GRIN2B 1717/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | KMO 248/4885SCN9A 2941/4885GRIN2B 1562/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | KMO 248/4885SCN9A 2941/4885GRIN2B 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.